Status:
UNKNOWN
Effect and Safety of Propofol Fumarate for Mother-to-child Blocking of Hepatitis B
Lead Sponsor:
Beijing Ditan Hospital
Conditions:
Chronic Hepatitis B Infection
High Viral Load
Eligibility:
FEMALE
18-35 years
Brief Summary
This study is a prospective study. The subject will select 440 cases of pregnant women with high hepatitis B virus load, and one group will take maternal and child blockade treatment with propofol fum...
Detailed Description
This study was a prospective cohort study. Because propofolofofovir is not covered by medical insurance and is more expensive, and there are factors such as renal function damage and the risk factors ...
Eligibility Criteria
Inclusion
- No nucleoside analog antiviral drugs have been used in the past.
- HBsAg and HBeAg double positive, HBV DNA\>106 IU/mL.
- Fully inform the risk to voluntarily join the study and sign the informed consent form.
Exclusion
- Combine other viral infections: such as HCV, HIV, CMV, etc.;
- amniocentesis during pregnancy;
- Liver cirrhosis and liver cancer;
- Other autoimmune diseases and liver diseases;
- fetal ultrasound screening in early and middle pregnancy found deformity.
Key Trial Info
Start Date :
August 1 2019
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
August 1 2021
Estimated Enrollment :
440 Patients enrolled
Trial Details
Trial ID
NCT04135235
Start Date
August 1 2019
End Date
August 1 2021
Last Update
October 22 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Beijing Ditan Hospital, Capital Medical University
Beijing, Beijing Municipality, China, 100015